Patent: 6,462,041
✉ Email this page to a colleague
Summary for Patent: 6,462,041
Title: | Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis |
Abstract: | The present invention is directed to gambogic acid, analogs and derivatives thereof, represented by the general Formulae I-III: ##STR1## wherein R.sub.1 -R.sub.5 are defined herein. The present invention also relates to the discovery that compounds having Formula I-III are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled cell growth and spread of abnormal cells occurs. |
Inventor(s): | Cai; Sui Xiong (San Diego, CA), Zhang; Han-Zhong (San Diego, CA), Wang; Yan (San Diego, CA), Tseng; Ben (San Diego, CA), Kasibhatla; Shailaja (San Diego, CA), Drewe; John A. (Costa Mesa, CA) |
Assignee: | Cytovia, Inc. (San Diego, CA) |
Application Number: | 09/495,120 |
Patent Claims: | see list of patent claims |
Details for Patent 6,462,041
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2019-05-21 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2019-05-21 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2019-05-21 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2019-05-21 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |